Synergistic Combinations

A general principle applies to all combination data here. Synergy in a cell line or animal model does not establish clinical safety or efficacy in combination. Drug interaction risks must be evaluated separately from biological synergy.

Chemotherapy combinations

Cisplatin

This is the best-supported chemosensitisation combination in the apigenin literature.

Apigenin enhances cisplatin cytotoxicity and apoptosis in a p53-dependent manner across lung, ovarian, colon, and osteosarcoma models. In cisplatin-resistant ovarian cancer cells (SKOV3/DPP), apigenin reversed resistance by downregulating MCL-1. In cisplatin-resistant colon xenograft models, apigenin inhibited tumour growth in vivo.

Doxorubicin and sorafenib

In hepatocellular carcinoma models, apigenin restores and enhances the antitumour effects of doxorubicin and sorafenib in both cell lines and mouse models.

5-fluorouracil, paclitaxel, and topoisomerase inhibitors

Apigenin sensitises cancer cells to 5-FU and paclitaxel across multiple cell-line studies. In leukaemia models, apigenin also sensitises cells to topoisomerase inhibitor agents, increasing apoptosis through a stronger DNA-damage response.

Most of this evidence remains cell-line based unless otherwise stated.

Gemcitabine

Preclinical reports show enhanced gemcitabine activity in pancreatic cancer cell models. Evidence remains in vitro only.

Immunotherapy combinations

No direct human or animal trials have tested apigenin with checkpoint inhibitor drugs.

The rationale rests on documented PD-L1 suppression and STAT3 inhibition in melanoma models. That makes the combination biologically plausible, but clinically untested.

Targeted therapy combinations

Imatinib

A rat pharmacokinetic study found a bidirectional, time-dependent interaction. Short-term apigenin exposure inhibited imatinib metabolism and raised imatinib concentrations. Long-term co-administration appeared to accelerate metabolism and lower concentrations.

This is not a synergy study. It is a genuine interaction warning for anyone using kinase inhibitors.

Olaparib

Apigenin modulates survival pathways and has been shown to restore olaparib sensitivity in vitro. This is early evidence, but relevant to PARP inhibitor resistance.

BH3 mimetics

Because apigenin suppresses MCL-1, which is a major resistance route to venetoclax and navitoclax, there is a strong mechanistic rationale for combining apigenin with BH3 mimetic strategies.

This remains mechanistic and cell-line supported. No clinical combination trials exist.

Natural-compound combinations

Quercetin and apigenin

Both compounds downregulate ABC transporter activity, including P-glycoprotein, MRP2, and BCRP. That may improve absorption and intracellular retention.

Biologically, quercetin pressures BCL-2/PI3K-AKT signalling, while apigenin adds MCL-1 pressure. That makes the pairing mechanistically layered rather than redundant.

Fisetin, quercetin, and apigenin — senolytic pulse layer

The three-compound Senolytic Pulse Protocol layers these compounds by survival-protein dependence:

• Fisetin: pressures BCL-xL-dependent senescent cells

• Quercetin + bromelain: pressures BCL-2/PI3K-AKT-dependent pathways while adding anti-inflammatory support

• Apigenin: follows up on MCL-1 and residual BCL-2/BCL-xL escape pathways in stressed and residual cells

The rationale is mechanistically coherent across cell and animal data. Combination safety and optimal sequencing in humans have not been established in formal studies.

References

• Arango D, et al. Apigenin enhances the cisplatin cytotoxic effect through p53-dependent apoptosis

• Qi Y, et al. Apigenin induces apoptosis and reverses drug resistance in ovarian cancer by decreasing Mcl-1

• Mahbub AA, et al. The effect of apigenin and chemotherapy combination treatments on leukemia cells

• Huang S, et al. Apigenin enhances sorafenib anti-tumour efficacy in hepatocellular carcinoma

• Lan T, et al. The Effect of Apigenin on Pharmacokinetics of Imatinib and Its Metabolite

• Lu Y, et al. Apigenin modulates cell survival pathways and restores olaparib sensitivity